It was alsoshown that GPR30 is able to upregulate aromatase expression in tamoxifen-resistant breastcancer cells, which can be linked to the sensitivity to AIs in breast cancer patients withacquired or de novo resistance to tamoxifen (Catalano et al. 2014). This evidence concerns the gene CYP19A1 and breast carcinoma.